FYR Bio is a biotechnology company specializing in the development of precision medicine tools through the use of extracellular vesicles (EVs). Their proprietary EV-Omics (EVO) platform utilizes AI-enabled multiomic insights to provide non-invasive, blood-based diagnostics and treatment options, particularly in the fields of oncology, neuro-oncology, and neurodegeneration. By enriching EVs from diseased cells, FYR Bio aims to transform personalized patient care, offering enhanced disease monitoring and improved therapeutic outcomes.